So I think we need to give a little kudos to our marketing team who’s really created a great website, a great informational portal for physicians. And we know what in our discussions with the IFCR and other alliance groups that many of these patients are treated on a more local basis, and they’re only going to their centers of excellence once or twice a year. So it’s clear to us that physicians are not necessarily waiting for those visits. Some are actively prescribing today. We’ve had several thousand hits from both caregivers and physicians on our website. And so we really feel we’re getting some great traction early days. And again, I’ll thank our publication team and Alex Aimetti team on driving that Phase 3 publication, a great editorial in the Lancet inclusion in the global CDKL5 guidelines as a recommended therapy.
All those things have, I think, really broadened the reach of the drug in early days. Again, early and we know that these families and patients have a lot of medical problems, see a lot of physicians. And so we know there’s going to be some rate limiting steps for families to get to physicians. But early days, again, we could not be happier with the depth and breadth of the launch. Does that helpful?
Douglas Tsao: Yes. No dues, Scott. And just as a follow-up, because I think, your point is €“ it’s an important one about not just seeing volumes from the COEs. I’m just curious, do you have a sense, I mean, I think you mentioned the website and knowledge of the Phase 3. Do you have a sense of, like, is there a pattern for folks who all €“ and I know it’s difficult because obviously you’re not necessarily interacting with them. But for these scripts that are just kind of €“ for lack of a better phrase, just kind of appearing in the system. Do you have a sense of where that awareness is coming from?
Scott Braunstein: I’m going to turn it over to Christy, who, as a reminder, has spent many years of her career in the rare orphan disease space. So Christy, maybe I’ll turn it over to you for maybe general comments about the ultra-orphan space and what you think we’re seeing early days here.
Christy Shafer: Yes, absolutely. So again, we had enormous kind of warm entry into the COE but a good amount of our time was spent out in the community understanding how these patients are moving between the COE and the community. So we have minimal amount of prescriptions that are, I would say, just showing up rather without any involvement from either our medical affairs team or direct promotional efforts from our sales team. So right now, again, to Scott’s point of understanding how these patients are being treated, when they’re showing up in the COE versus their community setting. We’re mapping that out right now, but again, this is a direct process by which a good promotional effort from not only our marketing medical affairs and promotional effort from our sales team.
Douglas Tsao: Okay. Great. Thank you.
Scott Braunstein: Thanks, Doug.
Operator: And we’ll take our next question from Jay Olson with Oppenheimer. Your line is open.
Jay Olson: Congrats on all the progress and thanks for taking the questions. Now that you sold the PRV, can you talk about how you plan to invest the $110 million proceeds and how are you prioritizing asset allocation? And then could you share any thoughts on business development opportunities to diversify your portfolio, especially since there are a number of assets available at relatively low valuations? Thank you.
